# Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia

> **NCT06450067** · — · RECRUITING · sponsor: **Juventas Cell Therapy Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06450067
- **Lead sponsor:** Juventas Cell Therapy Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-05
- **Primary completion:** 2026-06-05
- **Final completion:** 2029-06-05
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06450067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06450067, "Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06450067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*